Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
Learn about the latest bladder cancer clinical trial results and treatment advances from the 2025 ASCO Genitourinary Cancers Symposium in this 20-minute medical education video. Discover key findings from three major clinical trials that are shaping bladder cancer treatment protocols. Explore the NIAGARA trial results showing that pre-cystectomy circulating tumor DNA (ctDNA) positivity correlates with 97% non-pathologic complete response rates, while post-cystectomy ctDNA positivity indicates high disease relapse risk. Examine the EV302 trial outcomes demonstrating that enfortumab vedotin plus pembrolizumab (EV+P) combination therapy achieved superior overall response rates of 67.6% versus 44.2% compared to standard treatment, with responders showing 49% progression-free survival and 75% overall survival at 2 years. Review the JAVELIN BLADDER trial data revealing that sacituzumab govitecan combined with avelumab significantly improved overall response rates (24% vs 3%) and median progression-free survival (hazard ratio 0.49; 95% CI 0.31-0.76). Gain insights into how these clinical developments may influence future bladder cancer management strategies and patient care decisions from genitourinary oncology specialists at Dana-Farber Cancer Institute's Lank Center for Genitourinary Oncology.
